Posaconazole
| Evidence Level: L5 | Predicted Indications: 56 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Posaconazole |
| DrugBank ID | DB01263 |
| Brand Names (EU) | Posaconazole AHCL, Posaconazole Accord |
| Evidence Level | L5 |
| Predicted Indications | 56 |
| Top Prediction Score | 99.77% |
Approved Indication (EMA)
Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products; Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B; Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazol
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | pneumocystosis | 99.77% | DL |
| 2 | mycetoma | 99.36% | DL |
| 3 | aspergillosis | 98.98% | DL |
| 4 | vulvovaginal candidiasis | 98.92% | DL |
| 5 | leprosy | 98.84% | DL |
| 6 | candidiasis | 98.73% | DL |
| 7 | multibacillary leprosy | 98.61% | DL |
| 8 | Ambras type hypertrichosis universalis congenita | 98.55% | DL |
| 9 | malformation syndrome with odontal and/or periodontal component | 98.46% | DL |
| 10 | isolated genetic hair shaft abnormality | 98.44% | DL |
| 11 | syndrome with a Dandy-Walker malformation as major feature | 98.43% | DL |
| 12 | hypertrichosis (disease) | 98.35% | DL |
| 13 | fusariosis | 98.08% | DL |
| 14 | paucibacillary leprosy | 97.98% | DL |
| 15 | lepromatous leprosy | 97.84% | DL |
| 16 | borderline leprosy | 97.84% | DL |
| 17 | multidrug-resistant tuberculosis | 97.77% | DL |
| 18 | hyperargininemia | 97.50% | DL |
| 19 | Cryptococcal meningitis | 97.36% | DL |
| 20 | geotrichosis | 97.01% | DL |
Showing top 20 of 56 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.